2019-02-08

Intellectual Disability and Epilepsy

Shankar, Rohit

<http://hdl.handle.net/10026.1/17225>

10.1007/978-3-319-90083-4_10

Springer

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/328613153>

Intellectual Disability and Epilepsy

Chapter · January 2019

DOI: 10.1007/978-3-319-90083-4_10

CITATION

1

READS

159

3 authors:

Rohit Shankar

University of Plymouth

192 PUBLICATIONS 962 CITATIONS

[SEE PROFILE](#)

Lance Vincent Watkins

Swansea Bay University Health Board

25 PUBLICATIONS 102 CITATIONS

[SEE PROFILE](#)

Stephen Brown

University of Plymouth

65 PUBLICATIONS 2,091 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:

The UK Ep-ID research Register: Looking at outcomes of AEDs in people with ID [View project](#)

Functional Neuroscience [View project](#)

Metadata of the chapter that will be visualized online

Chapter Title	Intellectual Disability and Epilepsy	
Copyright Year	2019	
Copyright Holder	Springer Nature Switzerland AG	
Corresponding Author	Family Name	Shankar
	Particle	
	Given Name	Rohit
	Suffix	
	Division	
	Organization/University	Cornwall Partnership NHS Foundation Trust
	Address	Bodmin, UK
	Division	
	Organization/University	Exeter Medical School
	Address	Truro, UK
	Email	rohit.shankar@nhs.net
Author	Family Name	Watkins
	Particle	
	Given Name	Lance
	Suffix	
	Division	Mental Health and Learning Disability Delivery Unit, Neath Port Talbot CLDT
	Organization/University	Abertawe Bro Morgannwg University Health Board
	Address	Swansea, Wales, UK
Author	Family Name	Brown
	Particle	
	Given Name	Stephen
	Suffix	
	Division	
	Organization/University	Plymouth Postgraduate Medical School
	Address	Cornwall, UK

Abstract	<p>Epilepsy in people with intellectual disability is more than the sum of the two conditions. Diagnosis is challenging in the face of cognitive and communication difficulties and in some instances the need to rely on third party information and difficulties in accessing relevant investigations. Treatment is complicated by the lack of evidence specific to intellectual disability and associated neurodevelopmental comorbidities. The presence in many with associated physical and psychological co-morbidity in the face of treatment resistance and increased preponderance to side effects and challenging behavior makes epilepsy management in people with intellectual disability highly complex. It can be argued that specific understanding and skill sets are needed to help manage this vulnerable group. This book chapter looks to outline the unique challenges and questions to treatment this special population poses and looks to provide evidence based up to date answers where available.</p>	Q1
Keywords (separated by “ - ”)	<p>Epilepsy - Seizures - Intellectual disability - Learning disabilities - Mental retardation - Pervasive developmental disorder - Autism - Epileptic encephalopathies - Premature mortality - SUDEP - Challenging behavior - Neuropsychiatric - Treatment choices - Antiepileptic medication side effects</p>	

AUTHOR QUERIES

Q1 Please check whether the authors names and affiliations are presented correctly.

Intellectual Disability and Epilepsy

10

Rohit Shankar, Lance Watkins, and Stephen Brown

2

10.1 Introduction

3

Epilepsy is a chronic disorder of the brain characterized by a predisposition to seizure activity, and associated with long term neurobiological, psychological, and social effects. A seizure can be defined as a transient occurrence of neurological symptoms associated with abnormal neuronal activity in the brain. The semiology of the seizure event will vary dependent upon the origin of the abnormal or excessive neuronal activity and may present with sensory, motor, emotional, or behavioral disturbance [1]. Two unproved seizures with at least a day apart were needed to diagnose epilepsy but The International League against Epilepsy (ILAE) Task Force has since refined this definition. Now clinicians are advised to consider an epilepsy diagnosis in individuals with *one* unprovoked seizure in association with other known risk factors [2].

10.2 Classification

15

The new Classification of the Epilepsies developed by the ILAE Commission for Classification and Terminology proposes a multilevel classification system. Clinician's should aim to make a diagnosis at all levels (dependent upon

R. Shankar (✉)
Cornwall Partnership NHS Foundation Trust, Bodmin, UK

Exeter Medical School, Truro, UK
e-mail: rohit.shankar@nhs.net

L. Watkins
Mental Health and Learning Disability Delivery Unit, Neath Port Talbot CLDT, Abertawe Bro Morgannwg University Health Board, Swansea, Wales, UK

S. Brown
Plymouth Postgraduate Medical School, Cornwall, UK

t1.1 **Table 10.1** ILAE (2017) classification of seizure types [4]

AU3

t1.2	Focal Onset	Generalized onset	Unknown onset
t1.3	Aware/Impaired		
t1.4	awareness		
t1.5	Motor	Motor	Motor
t1.6		Tonic-clonic	Tonic-clonic
t1.7		Other motor (myoclonic, tonic,	Other motor (myoclonic, tonic,
t1.8		atonic, mixture)	atonic, mixture)
t1.9	Non-motor	Non-motor (absence)	Unclassified
t1.10	Focal to bilateral		
t1.11	tonic-clonic		

19 resources), while considering etiology of the epilepsy throughout the assess-
20 ment process [3] (Table 10.1).

- 21 1. *Seizure Type*—seizures are classified focal, generalized, and unknown onset.
22 2. *Epilepsy type*—as well as the seizure types above, good practice now considers
23 combined generalized and focal epilepsy. Such diagnoses are likely to require
24 investigations including characteristic findings on electroencephalogram (EEG).
25 3. *Epilepsy syndrome*—Cluster of symptoms including clinical history, seizure
26 type, EEG changes, typical findings on neuroimaging (MRI), and genetic
27 testing.

28 **10.3 Epidemiology**

29 The estimated prevalence of epilepsy in the general population may be anywhere
30 between 0.6 and 1% [5]. In comparison, the prevalence of epilepsy in the intellectu-
31 ally disabled population ranges between 14 and 44% depending upon case ascer-
32 tainment, with a proportional relationship with level of intellectual disability
33 (Table 10.2) [6–11]. An overall prevalence of 22% has been shown based on a
34 pooled meta-analysis of the data currently available [12].

35 Despite the clear relationship between epilepsy and intellectual disability
36 understanding this association can be complex (Table 10.3). There may be a
37 wide range of pathological processes influencing neurodevelopment at varying
38 stages [25, 26]. This suggests multifactorial etiology which often results in
39 multiple co-morbid conditions. People with intellectual disability and epilepsy
40 have more physical co-morbidities than those with intellectual disability with-
41 out epilepsy, which results in higher health costs and increased mortality rates
42 [27]. Intellectual disability in combination with epilepsy significantly raises
43 standardized mortality ratios and the highest rates of mortality are associated
44 with a high frequency of generalized seizures and profound intellectual dis-
45 ability [28]. In a UK investigation seizures and epilepsy were the most frequent
46 cause of potentially avoidable hospital admissions in people with intellectual
47 disability, equating to 40% of all emergency admissions in adults with

t2.1	Table 10.2 Prevalence of epilepsy and level of intellectual disability [12]	Mild	10%	t2.3
t2.2		Moderate, severe, profound	30%	t2.4
				t2.5

Table 10.3 Epilepsy syndromes and epilepsy phenotypes associated with intellectual disability t3.1

Syndrome	Genetic abnormality	Epilepsy phenotype	Management	t3.2
Dravet syndrome (severe myoclonic epilepsy)	SCN1A mutation	Febrile and non-febrile seizures in first 12 months of life Episodes of status epilepticus Intellectual decline in second year	Sodium channel blockers-Lamotrigine, phenytoin, and carbamazepine can aggravate seizures [13]	t3.3
Tuberous sclerosis	TSC1, TSC2	69% epilepsy [14] Onset in infancy, 30% infantile spasms. Infantile spasms-typical hypsarrhythmia EEG pattern [15]	May respond well to Vigabatrin [16] Noval therapeutic options include mTOR inhibitors [17]	t3.4 t3.5 t3.6 t3.7 t3.8 t3.9
GLUT1 deficiency	SLC2A1	Seizures in first 4 months of life Dystonia-including exercise induced dyskinesia	Ketogenic diet [18]	t3.10 t3.11 t3.12 t3.13 t3.14 t3.15
Down's syndrome	T21	Two peaks in seizure onset-first year of life after the age of 40 [19] Seizures may be associated with Alzheimer's dementia-generalized myoclonic seizures of high frequency and severity	Caution with AEDs with adverse cognitive profiles if dementia diagnosis present	t3.16 t3.17 t3.18 t3.19 t3.20 t3.21 t3.22 t3.23 t3.24 t3.25 t3.26 t3.27
Lennox-Gastaut syndrome (epileptic encephalopathy)		<i>Classic triad-</i> Seizures-multiple types, treatment resistant EEG findings-diffuse slow spike wave activity (≤ 2.5 Hz), with fast activity during sleep ID and neuropsychiatric symptoms [20]	Rufinamide may offer most benefit [21] Lamotrigine-improved seizure control, mood, and sociability [22] Clobazam-useful adjunct [23] Topiramate-improvement in drop attacks [24]	t3.28 t3.29 t3.30 t3.31 t3.32 t3.33 t3.34 t3.35 t3.36

intellectual disability [29]. Both epilepsy and intellectual disability are individually associated with psychiatric co-morbidities. In people with intellectual disability and active epilepsy there is further increased risk of mental illness [30]. The assessment of behavior and neuropsychiatric side effects in people with epilepsy and intellectual disability can be complex and require a multi-disciplinary approach.

People with intellectual disability and epilepsy are more likely to experience treatment resistant seizures with up to two-thirds showing a poor response to

Table 10.4 Important aspects of Epilepsy history

<i>Description of event</i> —Pre-ictal, Ictal, Post-ictal (abnormal movements, abnormal tone, warning signs (aura), triggers, duration, day/nocturnal, frequency, any other events, injuries/ complications—e.g., head injury, difficulty breathing.
<i>Inter-ictal changes</i> —mood, personality, behavior.
<i>Past history</i> —previous seizures/progression of epilepsy, history of febrile seizures as a child, previous history of head injury, history of significant medical conditions, genetics, family history of epilepsy or neurological disorder.

anti-epileptic medication [8]. The combination of intellectual disability, treatment resistant epilepsy, and neurological deficits is often associated with genetic abnormalities or underlying structural pathology [31]. Uncontrolled epilepsy can have serious negative consequences on both quality of life and mortality [32]. There is a limited evidence base to support the prescribing of anti-epileptic medication in this vulnerable population [33] Supporting people with intellectual disability and epilepsy especially those with poorly controlled epilepsy requires high levels of competence and confidence in staff in community settings [34].

10.4 Diagnosis

Epilepsy is primarily a clinical diagnosis and should be made by a medical practitioner with training and expertise in epilepsy. In order to establish a diagnosis of epilepsy a thorough history is required with good collateral information and witness reports of the event (Table 10.4). This is particularly important for people with intellectual disability who may have cognitive and communication deficits. It is preferable to obtain a detailed description of events including the pre-ictal, ictal, and post-ictal period. It is useful if this information is provided in a standardized way using validated seizure monitoring tools [35]. There may be benefit in video-recording events. This will require the consent of the patient, or if the individual lacks capacity a formal review should take place with all interested parties to assess whether it is in the individuals best interests.

10.5 Differential Diagnosis

There are a wide range of events that can mimic the presentation of a seizure (Table 10.5). Identifying a seizure disorder in the intellectual disabled population is further complicated by levels of cognitive impairment, communication difficulties, and associate co-morbidities. People with epilepsy and intellectual disability have higher rates of stereotyped motor behaviors often associated with neurodevelopmental disorders such as autism [36]. It has been shown that up to 25% persons with intellectual disability and epilepsy referred to a specialist center have been misdiagnosed [37].

Table 10.5 Differential diagnoses for seizures in people with intellectual disability	t5.1
<i>Cardiac</i> —Syncope (vasovagal, orthostatic hypotension, arrhythmia)	t5.2
<i>Psychological</i> —panic attack, dissociative disorder, psychosis, affective disorder, Non epileptic seizure	t5.3 t5.4
<i>Behavioral disorder</i> —stereotypies, sensory seeking behavior- including self-injurious behavior (SIB), compulsions	t5.5 t5.6
<i>Vascular</i> —migraine, transient ischemic attacks (TIA), transient global amnesia (TGA)	t5.7
<i>Metabolic</i> —hypoglycemia, insulinoma, hyponatremia, hypocalcaemia	t5.8
<i>Sleep disorder</i> —parasomnia, narcolepsy, enuresis, nightmares	t5.9
<i>Movement disorder</i> —paroxysmal dyskinesia	t5.10
<i>Toxic state</i> —alcohol, illicit substances, toxicity of prescribed medication	t5.11

10.6 Epilepsy and Behavior 86

There are some key differences to be mindful of when considering the difference between a seizure and a behavioral disturbance. As a rule a seizure usually presents with similar behavior during each event. There is generally no clear precipitant and the individual will be unresponsive to attempts to communicate during the event. There is also the potential for behavioral or neuropsychiatric disturbance to occur as part of the complex epilepsy course. These symptoms may present during the perictal (pre-ictal, ictal, post-ictal) or inter-ictal period. There are added complexities to consider in the pharmacological management of epilepsy including the potential neuropsychiatric effects of AEDs, and the impact of psychotropic medications on seizure control.

10.7 Investigations 97

A special report by the UK chapter intellectual disability working group of the ILAE has shown that people with epilepsy and intellectual disability wait longer for routine investigations including EEG and MRI brain imaging [35]. This may be a result of inequality in access to specialist care provision [34]. Services need to ensure that the reasonable adjustments required are put in place so that this vulnerable population have access to the relevant investigations required [35]. The use of video EEG alongside telemetry can be particularly helpful in differentiating seizures from other behaviors in this population. It has been shown that there is a high rate of abnormality detection on MRI brain in those individuals with intellectual disability who undergo investigation [38].

It is important to note that a normal EEG between seizures does not rule out epilepsy. The ideal scenario is to capture an event during the EEG recording. The presence of epileptiform activity on EEG is also possible in people without epilepsy, particularly people with intellectual disability [39]. MRI has essentially replaced CT as the imaging of choice for epilepsy because of its sensitivity and specificity in identifying structural lesions that could be the origin of epileptic

discharges. However, MRI is not always widely available, and CT may be the most appropriate choice in an emergency. It is not uncommon for people with intellectual disability and associated co-morbidities to find it difficult to tolerate brain imaging. It may necessary to use sedation or even general anesthetic in order to complete investigations that require such an investigation in the person's best interest. If this is the case then capacity of the individual to consent must be assessed. Where the individual lacks the capacity to make an informed decision there should be a formal best interest's process as identified by the local legal processes weighing up the benefits and risks of such procedures and recorded accordingly. Electrocardiogram (ECG) and laboratory blood investigation are also an important part of the diagnosis process and will help rule out any potential other causes of events.

10.8 Treatment

A mainstay of epilepsy treatment is the prescription of AEDs. To date there is very little evidence-based research for AED prescribing in people with ID [33]. A Cochrane review into the pharmacological interventions for epilepsy in people with ID highlights the lack of evidence to support the efficacy, side-effect profile, and safety of AEDs for people with ID [40]. The treatment of epilepsy requires a person-centered approach with consideration to each stage of the ILAE classification of epilepsies [4]. This is perhaps more relevant to the ID population where there will be particular concerns over the potential cognitive and behavioral side effects of AEDs.

10.8.1 Pharmacological Management

A large proportion of people with intellectual disability and epilepsy experience a chronic refractory course, with up to 40% receiving multiple AEDs but still experiencing poor seizure control [41]. In the UK the Royal College of Psychiatrists (RCPsych) College Report CR206 (2017) is a technical paper advising on the prescription of AEDs for people with epilepsy and intellectual disability, based on current evidence. This paper explores the potential for drug interactions, AED formulation, and the management of neuropsychiatric co-morbidities. The College Report provides a simplified 'traffic light system' (first line, second line, and avoid) approach to AED prescription for people with intellectual disability.

The adverse effects of AEDs are more commonly observed when high doses are prescribed and dose titration is rapid [42]. Therefore it is recommended that AEDs are introduced at low dose and titration is slow, reducing the likelihood of dose related adverse effects. When adding a new drug it is recommended that a therapeutic dose is established before removing the old drug. This will help attribute any changes in efficacy or side effect profile more easily [43].

10.9 Lamotrigine (First Line) 153

Lamotrigine has been shown to be well tolerated in the intellectual disability population, with good efficacy in seizure control and improvement on a range of quality of life measures [44]. Lamotrigine is known to have mood stabilizing properties and a randomized open-label investigation not only showed improved seizure control but improvements in challenging behavior [45]. There is specific evidence to show that Lamotrigine improves seizure control and a wide range of quality of life and social measures in people with Lennox-Gastaut syndrome [46].

10.10 Sodium Valproate (First Line) 161

The evidence suggests that valproate is a broad spectrum treatment option that can be used for a variety of seizure types with a good safety profile [47]. It is a first-line treatment for primary generalized seizures and is recommended for use for people with treatment resistant seizures, and people with intellectual disability may be more responsive [33]. The main limitations to the widespread use of valproate are the side effect profile. Along with more common effect such as weight gain, valproate is known to have significant teratogenic effects and is therefore not recommended for women of child bearing age. This needs careful considerations in the intellectual disabled population for any women with borderline or mild intellectual disability who may be sexually active.

10.11 Topiramate (Second Line) 172

The efficacy of topiramate has been investigated through a number of randomized, placebo-controlled, add-on design trials. These investigations show good improvements in seizure control, however the power of the studies is too low to demonstrate statistically significant findings. Importantly no significant effect on behavior was observed [48]. There is evidence that topiramate may be effective against a wide range of seizure types, particularly dangerous atonic seizures observed in Lennox-Gastaut syndrome [49].

10.12 Levetiracetam (Second Line) 180

Levetiracetam appears to be generally well tolerated in the intellectual disabled population with improvement in seizure control and increased seizure freedom rates in open study designs [50]. An association between levetiracetam and neuropsychiatric side effects, particularly aggression has been observed, and these effects may be more common in people with intellectual disability [51]. As with most AEDs, the risk of neuropsychiatric side effects increases with a previous psychiatric history [52].

10.13 Carbamazepine (Second Line)

There is a very limited evidence base to support the efficacy of carbamazepine specifically in people with intellectual disability. There is evidence to suggest that slow release preparations may be better tolerated in the intellectual disabled population [53]. Carbamazepine is known to have a number of associated adverse effects including hyponatremia, sedation, dizziness, and bone marrow suppression. Carbamazepine also interacts with many other drugs which can significantly alter their efficacy and requires consideration before prescribing [43]. *Oxcarbazepine* has been investigated in an add on trial in children with good efficacy but relatively poor tolerability with the need for dose reduction or discontinuation in one fifth of cases [54].

10.14 Lacosamide (Second Line)

An open label retrospective investigation suggests that lacosamide may be a useful adjunct for people with intellectual disability and treatment resistant epilepsy. However, the evidence base is very limited and caution is therefore advised with interpretation [55].

10.15 Perampanel (Second Line)

In a multi-center retrospective case series perampanel was found to be safe and well tolerated, with good improvement in seizure control as an adjunctive agent [56]. However, there is evidence to suggest an increased risk of psychiatric side effects in people with intellectual disability. A cross sectional study identified that over half of the patients involved experience behavioral changes, most notably aggression [57]. It is therefore advised that caution is taken if prescribing for individuals with a previous history of behavioral disorder or psychiatric illness.

10.16 AEDs to Avoid

Older AEDs such as phenobarbitone and phenytoin should not be prescribed for people with intellectual disability without good reason and only if it is in that individual's best interests. Such medications are associated with significant side effect profiles including a detrimental impact upon cognition, behavioral disturbance, multiple drug interactions, and encephalopathy at toxic levels [58].

10.17 Other AEDs

Newer AEDs have little to no evidence base for prescribing for people with epilepsy and intellectual disability. AEDs such as pregabalin, brivaracetam, tiagabine, and zonisamide may be used more routinely in clinical practice as second/third/fourth

line agents for treatment resistant seizures. However, efficacy, safety and tolerability have yet to be rigorously assessed in this population.

The UK Ep intellectual disabilities—research Register is a National Institute of Health Research adopted project undertaking a retrospective cohort study of real world outcomes, including tolerability and efficacy of AEDs in people with epilepsy and intellectual disability [33]. A recent investigation into perampanel by the Register has highlighted that people with moderate to profound intellectual disability are less likely to drop out- possibly due to their inability to report or communicate subjective side effects. This lower dropout rate was associated with higher rates of seizure improvement due to higher rates of retention and compliance [56]. Health care professionals have a role in educating patients, caregivers and families to understand epilepsy, the rationale for treatment, reduce stigma, and developing positive relationships. People with intellectual disability and their caregivers may not understand the importance of adhering to a treatment regime. A simple regime, the use of pictures and close liaison with the pharmacist all help. The use of pictures to communicate with people with intellectual disability can help such as the Books beyond words series [59].

10.18 Non-Pharmacological Interventions

10.18.1 Epilepsy Surgery

Intellectual disability is not, and should not be considered a contraindication for resective surgery [60]. In fact there is evidence to demonstrate that surgical intervention can improve both the behavioral and cognitive functioning of some people with epilepsy and ID [61]. For people with intellectual disability and treatment resistant epilepsy surgical intervention has been associated with improvement in seizure freedom compared to medical treatment, alongside improved quality of life measures [62].

10.18.2 Vagus Nerve Stimulation

Vagus nerve stimulation is indicated for use as an adjunctive therapy and can reduce the frequency of seizures in adults who remain refractory with AED treatment, and are not suitable for resective surgery [63]. Vagus nerve stimulation is a relatively safe surgical intervention for patients with intellectual disability [64]. There are some important short and long-term effects of vagus nerve stimulation to consider including the potential for impact upon normal cardiac conduction [65].

10.18.3 Ketogenic Diet

A Ketogenic diet is essentially high in fat and low in carbohydrates. There is evidence to support its efficacy in improving seizure control, specifically in Dravet

syndrome and Glut1 deficiency [66]. However, a Cochrane review of non-pharmacological interventions for adults with epilepsy and intellectual disability shows the lack of evidence available in this population. One of the main drawbacks of the diet is its tolerability [67].

10.19 Risk Management

The risks associated with epilepsy can be complex and wide ranging. We have to consider the impact of seizures themselves upon mortality, injury, and hospitalization. We also have to appreciate the wider impact of a chronic epilepsy course upon psychological, emotional, and social functioning. The approach to risk assessment and management should be person centered and evidence based. This will usually involve assessing the patient's level of risk and depends on the individual, their environment, frequency and severity of epilepsy. There are certain risks that are increased with people with intellectual disability and it is important that healthcare professionals are aware of these higher risks and discuss them with the individual, their families and/or caregivers. Any assessment should also include a basic analysis of risk associated with bathing and showering, preparing food, using electrical equipment, managing prolonged or serial seizures, the impact of epilepsy in social settings, and the suitability of independent living [68, 69].

10.20 Sudden Unexpected Death in Epilepsy (SUDEP)

Sudden unexpected Death in Epilepsy is the sudden and unexpected death of a person with epilepsy when no identifiable cause of death is made following post-mortem examination and toxicology [70]. The diagnosis of SUDEP is not straightforward and is essentially one of exclusion. The classification of SUDEP has more recently been further refined [71]. The incidence of sudden death appears to be 20 times higher in patients with epilepsy compared to the general population, and SUDEP is the most common cause of epilepsy related death [72]. The risk of SUDEP is increased for people with intellectual disability and treatment resistant epilepsy [73]. The UK NICE Clinical guidelines on the epilepsies [60] recommend that patient's, caregivers and families need to be counselled using information tailored to the patient's relative risk of SUDEP. The SUDEP and Seizure Safety Checklist is an evidence based tool that can be used to both assess and communicate risk with patient, their families and caregivers [72]. Effectively assessing and managing risk factors using a person centered approach can reduce the number of epilepsy relate deaths in people with intellectual disability (Table 10.6) [74–76].

Table 10.6 Desirable standards of care in the management of SUDEP [77]	t6.1
• Seizure frequency: maximize seizure control (GTC and nocturnal seizures) with pharmacological and non-pharmacological treatment. <u>Aim for less than 3 seizures pre year.</u>	t6.2 t6.3
• Collateral risk: Work collaboratively with patient, families, and caregivers to deliver person centered risk reduction. Including advocating nocturnal supervision where indicated.	t6.4 t6.5
• Access to care: Ensure equitable access to specialist review and reasonable adjustments for people with intellectual disability.	t6.6 t6.7
• Comorbidities: Detailed assessment of physical and psychological co-morbidities including genetic testing, and liaison with relevant specialists.	t6.8 t6.9

10.21 Status Epilepticus 291

People with intellectual disability are more likely to experience status epilepticus and associated mortality rates are higher [78]. Status epilepticus is an emergency and may warrant the prescription of a rescue medication protocol to reduce the risk of potential harmful effects. Treatment should be given if the individual has a prolonged convulsive seizure that lasts for 5 min or more or if seizure occurs 3 or more times in an hour [60]. Rescue protocols can and should be adapted to ensure they are tailored specifically to an individual’s needs and identified risks. Standardized guidelines on training standards and practice are available from the Joint Epilepsy Council of the United Kingdom and Ireland. Any rescue medication must be administered by an appropriately trained person. Training should include an overview of epilepsy and associated risk factors in order to help ensure safe administration of rescue medication by family members or care staff. Treatment options available in the community include buccal midazolam (first-line treatment) and rectal diazepam (if midazolam is not suitable).

Benzodiazepines can be used as both rescue medication and as an effective add-on treatment in refractory epilepsy. Clobazam in particular is recognized as being especially useful as intermittent rescue treatment, often used to manage cluster seizures. Clobazam is considered appropriate to use regularly as second line or adjunct therapy for all major seizure types. A major concern is the development of tolerance, however around 30% of people with epilepsy prescribed clobazam could continue without experiencing long-term tolerance [33].

Conclusion 313

The management of epilepsy in the intellectually disabled population is complex, not least owing to the level of cognitive impairment and communication difficulties. The intellectually disabled population is more likely to have treatment resistant epilepsy and multiple associated co-morbidities. Each case requires a person centered approach considering all aspects of epilepsy including seizures themselves, risk assessment, and the psychological and social impact of a multifacto-

rial chronic disorder. The UK RCPsych has published two recent college reports detailing delivery of epilepsy care [79] and the approach to prescribing [43] for people with intellectual disability.

The delivery of epilepsy care to people with intellectual disability has been shown to be fragmented and at times inadequate due to inequalities in access to specialist care [34]. There is a need for improved collaboration between all professional bodies involved in the delivery of care to this population, with improvement in standards of assessment, information gathering, and the education and training of healthcare staff, families or caregivers [35].

References

1. Fisher RS, Boas WVE, Blume W, Elger C, Genton P, Lee P, Engel J. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia*. 2005;46:470–2.
2. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J, Forsgren L, French JA, Glynn M, Hesdorffer DC. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia*. 2014;55:475–82.
3. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. *Epilepsia*. 2017;58:512–21.
4. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL, Peltola J, Roulet Perez E, Scheffer IE. Operational classification of seizure types by the International league against epilepsy: position paper of the ILAE commission for classification and terminology. *Epilepsia*. 2017;58:522–30.
5. De Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. *Epilepsy Behav*. 2008;12:540–6.
6. Mariani E, Ferini-Strambi L, Sala M, Erminio C, Smirne S. Epilepsy in institutionalized patients with encephalopathy: Clinical aspects and nosological considerations. *Am J Ment Retard*. 1993;98(Suppl):27–33.
7. Matthews T, Weston N, Baxter H, Felce D, Kerr M. A general practice-based prevalence study of epilepsy among adults with intellectual disabilities and of its association with psychiatric disorder, behaviour disturbance and carer stress. *J Intellect Disabil Res*. 2008;52:163–73.
8. McGrother CW, Bhaumik S, Thorp CF, Hauck A, Branford D, Watson JM. Epilepsy in adults with intellectual disabilities: prevalence, associations and service implications. *Seizure*. 2006;15:376–86.
9. Morgan CL, Baxter H, Kerr MP. Prevalence of epilepsy and associated health service utilization and mortality among patients with intellectual disability. *Am J Ment Retard*. 2003;108:293–300.
10. Richardson SA, Koller H, Katz M, McLaren J. A functional classification of seizures and its distribution in a mentally retarded population. *Am J Ment Defic*. 1981;85:457–66.
11. Steffenburg U, Hagberg G, Kyllerman M. Active epilepsy in mentally retarded children. II. Etiology and reduced pre- and perinatal optimality. *Acta Paediatr*. 1995;84:1153–9.
12. Robertson J, Hutton C, Emerson E, Baines S. Prevalence of epilepsy among people with intellectual disabilities: a systematic review. *Seizure*. 2015a;29:46–62.
13. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. *Epilepsia*. 1998;39:508–12.
14. Webb DW, Fryer AE, Osborne JP. On the incidence of fits and mental retardation in tuberous sclerosis. *J Med Genet*. 1991;28:395–7.

15. Saxena A, Sampson JR. Epilepsy in tuberous sclerosis: phenotypes, mechanisms, and treatments. In: *Seminars in neurology*, vol. 35. Germany: Thieme Medical Publishers; 2015. p. 269–76. 368 369 370
16. Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. *Eur J Paediatr Neurol*. 2002;6:15–23. 371 372
17. Curatolo P, Bjørnvold M, Dill PE, Ferreira JC, Feucht M, Hertzberg C, Jansen A, Jóźwiak S, Kingswood JC, Kotulska K, Macaya A. The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions. *Drugs*. 2016;76:551–65. 373 374 375 376
18. Klepper J, Scheffer H, Leiendecker B, Gertsen E, Binder S, Leferink M, Hertzberg C, Näke A, Voit T, Willemsen MA. Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2-to 5-year follow-up of 15 children enrolled prospectively. *Neuropediatrics*. 2005;36:302–8. 377 378 379 380
19. Pueschel SM, Louis S, McKnight P. Seizure disorders in Down syndrome. *Arch Neurol*. 1991;48:318–20. 381 382
20. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshé SL. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia*. 2010;51:676–85. 383 384 385 386
21. Besag FM. Rufinamide for the treatment of Lennox–Gastaut syndrome. *Expert Opin Pharmacother*. 2011;12:801–6. 387 388
22. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. *Lamictal Lennox–Gastaut Study Group*. *N Engl J Med*. 1997;18:1807–12. 389 390 391
23. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in Lennox–Gastaut syndrome. *Neurology*. 2011;77:1473–81. 392 393
24. Sachdeo RC, Glauser TA, Ritter FO, Reife R, Lim P, Pledger G, Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. *Neurology*. 1999;52:1882. 394 395 396
25. Bowley C, Kerr M. Epilepsy and intellectual disability. *J Intellect Disabil Res*. 2000;44:529–43. 397
26. Lhatoo SD, Sander JWAS. The epidemiology of epilepsy and learning disability. *Epilepsia*. 2001;42(s1):6–9. 398 399
27. Robertson J, Baines S, Emerson E, Hatton C. Service responses to people with intellectual disabilities and epilepsy: a systematic review. *J Appl Res Intellect Disabil*. 2015b;30:1–32. 400 401
28. Forsgren L, Edvinsson SO, Nyström L, Blomquist HK. Influence of epilepsy on mortality in mental retardation: an epidemiologic study. *Epilepsia*. 1996;37:956–63. 402 403
29. Glover G, Evison F. Hospital admissions that should not happen. Lancaster: Improving Health and Lives: Learning Disabilities Observatory; 2013. 404 405
30. Turkey A, Felce D, Jones G, Kerr M. A prospective case control study of psychiatric disorders in adults with epilepsy and intellectual disability. *Epilepsia*. 2011;52:1223–30. 406 407
31. Busch RM, Najm I, Hermann BP, Eng C. Genetics of cognition in epilepsy. *Epilepsy Behav*. 2014;41:297–306. 408 409
32. Kerr M, Bowley C. Evidence-based prescribing in adults with learning disability and epilepsy. *Epilepsia*. 2001;42(s1):44–5. 410 411
33. Doran Z, Shankar R, Keezer MR, Dale C, McLean B, Kerr MP, Devapriam J, Craig J, Sander JW. Managing anti-epileptic drug treatment in adult patients with intellectual disability: a serious conundrum. *Eur J Neurol*. 2016;23:1152–7. 412 413 414
34. Kerr M, Linehan C, Thompson R, Mula M, Gil-Nagal A, Zuberi SM, Glynn M. A White Paper on the medical and social needs of people with epilepsy and intellectual disability: the task force on intellectual disabilities and epilepsy of the international league against epilepsy. *Epilepsia*. 2014;55:1902–6. 415 416 417 418
35. Kerr MP, Watkins LV, Angus-Leppan H, Goodwin M, Hanson C, Roy A, Shankar R. The provision of care to adults with an intellectual disability in the UK. A Special report from the intellectual disability UK chapter ILAE. *Seizure*. 2018;56:41–6. 419 420 421

36. Paul A. Epilepsy or stereotypy? Diagnostic issues in learning disabilities. *Seizure*. 1997;6:111–20.
37. Donat JF, Wright FS. Episodic symptoms mistaken for seizures in the neurologically impaired child. *Neurology*. 1990;40:156.
38. Andrews TM, Everitt AD, Sander JWAS. A descriptive survey of long-term residents with epilepsy and intellectual disability at the Chalfont Centre: is there a relationship between maladaptive behaviour and magnetic resonance imaging findings? *J Intellect Disabil Res*. 1999;43:475–83.
39. Gregory RP, Oates T, Merry RTG. Electroencephalogram epileptiform abnormalities in candidates for aircrew training. *Electroencephalogr Clin Neurophysiol*. 1993;86:75–7.
40. Beavis J, Kerr M, Marson AG, Dojcinov I. Pharmacological interventions for epilepsy in people with intellectual disabilities. *Cochrane Database Syst Rev*. 2007a;9:CD005399.
41. Espie CA, Gillies JB, Montgomery JM. Antiepileptic polypharmacy, psychosocial behaviour and locus of control orientation among mentally handicapped adults living in the community. *J Intellect Disabil Res*. 1990;34:351–60.
42. Kerr MP, Mensah S, Besag F, De Toffol B, Ettinger A, Kanemoto K, Kanner A, Kemp S, Krishnamoorthy E, LaFrance WC Jr, Mula M. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. *Epilepsia*. 2011;52:2133–8.
43. Royal College of Psychiatrists. Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability, College Report CR206. In: Royal College of Psychiatrists; 2017a. <https://www.rcpsych.ac.uk/files/pdfversion/CR206.pdf>.
44. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. *Seizure*. 1996;5(2):149–51.
45. Crawford P, Brown S, Kerr M, Parke Davis Clinical Trials Group. A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. *Seizure*. 2001;10:107–15.
46. Trevathan E, Motte J, Arvidsson J, Manasco P, Mullens L. Safety and tolerability of adjunctive Lamictal for the treatment of the Lennox-Gastaut syndrome: results of multinational, double-blind, placebo-controlled trial. *Epilepsia*. 1996;37(Suppl 5):S202.
47. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. *Lancet*. 2007;369:1016–26.
48. Kerr MP, Baker GA, Brodie MJ. A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. *Epilepsy Behav*. 2005;7:472–80.
49. Kerr MP. Topiramate: uses in people with an intellectual disability who have epilepsy. *J Intellect Disabil Res*. 1998;42:74–9.
50. Kelly K, Stephen LJ, Brodie MJ. Levetiracetam for people with mental retardation and refractory epilepsy. *Epilepsy Behav*. 2004;5:878–83.
51. Helmstaedter C, Fritz NE, Kockelmann E, Kosanetzky N, Elger CE. Positive and negative psychotropic effects of levetiracetam. *Epilepsy Behav*. 2008;13:535–41.
52. Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. *Seizure*. 2004;13:55–7.
53. Kaski M, Heinonen E, Sivenius J, Tuominen J, Anttila M. Treatment of epilepsy in mentally retarded patients with a slow-release carbamazepine preparation. *J Intellect Disabil Res*. 1991;35:231–9.
54. Gaily E, Granström ML, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. *J Intellect Disabil Res*. 1998;42:41–5.
55. Flores L, Kemp S, Colbeck K, Moran N, Quirk J, Ramkolea P, von Oertzen TJ, Nashef L, Richardson MP, Goulding P, Elwes R. Clinical experience with oral lacosamide as adjunctive

- therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK). *Seizure*. 2012;21:512–7. 475
56. Shankar R, Henley W, Wehner T, Wiggans C, McLean B, Pace A, Mohan M, Sadler M, Doran Z, Hudson S, Allard J. Perampanel in the general population and in people with intellectual disability: Differing responses. *Seizure*. 2017a;49:30–5. 477
57. Andres E, Kerling F, Hamer H, Kasper B, Winterholler M. Behavioural changes in patients with intellectual disability treated with perampanel. *Acta Neurol Scand*. 2017;136: 478
- 645–53. 479
58. Livanainen M. Phenytoin: effective but insidious therapy for epilepsy in people with intellectual disability. *J Intellect Disabil Res*. 1998;42:24–31. 480
59. Bradley E, Hollins S. Books beyond words: using pictures to communicate. *J Dev Disabil*. 2013;19:24–32. 481
60. NICE clinical guideline 137 (2012) The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. <https://www.nice.org.uk/guidance/cg137>. 482
61. Kerr M, Linehan C, Brandt C, Kanemoto K, Kawasaki J, Sugai K, Tadokoro Y, Villanueva V, Wilmshurst J, Wilson S. Behavioral disorder in people with an intellectual disability and epilepsy: a report of the intellectual disability task force of the neuropsychiatric commission of ILAE. *Epilepsia Open*. 2016;1:102–11. 483
62. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. *N Engl J Med*. 2001;345:311–8. 484
63. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response: a review. *J Neurosurg*. 2011;115:1248–55. 485
64. Prasher VP, Kerr M. *Epilepsy and intellectual disabilities*. 2nd ed. Cham: Springer; 2016. 486
65. Shankar R, Olotu VO, Cole N, Sullivan H, Jory C. Case report: vagal nerve stimulation and late onset asystole. *Seizure*. 2013a;22:312–4. 487
66. Hee Seo J, Mock Lee Y, Soo Lee J, Chul Kang H, Dong Kim H. Efficacy and tolerability of the ketogenic diet according to lipid: nonlipid ratios—comparison of 3: 1 with 4: 1 diet. *Epilepsia*. 2007;48:801–5. 488
67. Beavis J, Kerr M, Marson AG, Dojcinov I. Non-pharmacological intervention for epilepsy in people with intellectual disabilities. *Cochrane Database Syst Rev*. 2007b;9:CD005502. 489
68. Besag FM. Lesson of the week: tonic seizures are a particular risk factor for drowning in people with epilepsy. *BMJ*. 2001;322(7292):975. 490
69. Forjuoh SN, Guyer B. Injury prevention in people with disabilities: Risks can be minimised without unduly restricting activities. *Br Med J*. 2001;322:940–1. 491
70. Nashef L. Sudden unexpected death in epilepsy: terminology and definitions. *Epilepsia*. 1997;38(s11):S6–8. <https://doi.org/10.1111/j.1528-1157.1997.tb06130.x>. 492
71. Nashef L, So EL, Ryvlin P, Tomson T. Unifying the definitions of sudden unexpected death in epilepsy. *Epilepsia*. 2012;53:227–33. 493
72. Shankar R, Cox D, Jaliha V, Brown S, Hanna J, McLean B. Sudden unexpected death in epilepsy (SUDEP): development of a safety checklist. *Seizure*. 2013b;22:812–7. 494
73. Hesdorffer DC, Tomson T, Benn E, Sander JW, Nilsson L, Langan Y, Walczak TS, Beghi E, Brodie MJ, Hauser A. Combined analysis of risk factors for SUDEP. *Epilepsia*. 2011;52: 495
- 1150–9. 496
74. Shankar R, Jaliha V, Walker M, Laugharne R, McLean B, Carlyon E, Hanna J, Brown S, Jory C, Tripp M, Pace A. A community study in Cornwall UK of sudden unexpected death in epilepsy (SUDEP) in a 9-year population sample. *Seizure*. 2014;23:382–5. 497
75. Shankar R, Walker M, McLean B, Laugharne R, Ferrand F, Hanna J, Newman C. Steps to prevent SUDEP: the validity of risk factors in the SUDEP and seizure safety checklist: a case control study. *J Neurol*. 2016;263:1840–6. 498
76. Shankar R, Donner EJ, McLean B, Nashef L, Tomson T. Sudden unexpected death in epilepsy (SUDEP): what every neurologist should know. *Epileptic Disord*. 2017b; 499
- 19:1–9. 500

528 77. Watkins L, Shankar R, Sander JW. Identifying and mitigating Sudden Unexpected Death in
529 Epilepsy (SUDEP) risk factors. *Expert Rev Neurother*. 2018;18:265–74.
530 78. Pellock JM, Morton LD. Treatment of epilepsy in the multiply handicapped. *Dev Disabil Res*
531 *Rev*. 2000;6:309–23.
532 79. Royal College of Psychiatrists. The management of epilepsy in adults with intellectual disabil-
533 ity, College Report CR203. In: Royal College of Psychiatrists; 2017b. [https://www.rcpsych.](https://www.rcpsych.ac.uk/files/pdfversion/CR203.pdf)
534 [ac.uk/files/pdfversion/CR203.pdf](https://www.rcpsych.ac.uk/files/pdfversion/CR203.pdf).

Uncorrected Proof

Author Queries

Chapter No.: 10 0004157403

Queries	Details Required	Author's Response
AU2	Please check the hierarchy of the section headings and confirm if correct.	
AU3	Please check whether the presentation and placement of Tables 10.1 to 10.6 are okay as typeset.	
AU4	As per style references have been changed from “name and year” to “numbered” format. Please check whether the citations are appropriate.	